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ABSTRACT 
FHIT encompasses the fragile site FRA3B on chromosome 3 which can be lost and cause 
genome-wide DNA instability. This instability can cause the loss or mutation of other caretaker 
genes such as BRAC1/2 genes which causes a specific mutational signature. The mutation 
profile of FHIT loss closely resembles the mutational signature 5 which suggests that loss of 
FHIT could be a marker for cancer development as well as a target for prevention of cancer 
initiation. Loss of FHIT expression occurs due to replication stress at the FHIT locus, at very low 
levels, which leads to genome -wide DNA instability in the FHIT deficient cells through the 
reduced expression of the TK1 gene which is needed for normal DNA replication. Genome 
instability and mutation accumulation in Fhit-deficient cells in tissue culture can be prevented 
through supplementation with low dose thymidine in the culture medium. It was tested to 
determine if low dose thymidine supplementation can prevent genome instability in vivo, reduce 
mutation accumulation and prevent development of cancerous lesions in FHIT-deficient versus 
sufficient mice, without causing imbalance of cellular dNTP pools for DNA synthesis, a possible 
deleterious side-effect. A preclinical mouse model using male and female mice ten weeks of age 
and 50% each gender made up cohorts, eight mice each, which were FHIT +/+ or +/-. Half of 
each cohort (4 mice each) were treated with or without thymidine supplementation (1.8 g/kg 
thymidine). Mice receiving the diet without thymidine are pair-fed to allow ingestion of the same 
amount as thymidine supplemented mice. The mice were euthanized ten weeks after treatment 
and the tumor development was examined. Tumor burdens did not appear significantly different 
between +/+ and +/- mice. Histology must be done to further differentiate the tumor types. The 
research is innovative in using replacement of the scavenger thymidine pathway in vivo, a 
pathway lost as a direct result of FHIT loss, to counteract genome instability, a major 
downstream effect of lost FHIT genome caretaker and tumor suppressor function, and thus 
restore those functions to prevent tumor development. 
INTRODUCTION 
Findings leading to report of significant association of FHIT loss with signature 5 mutations: 
FHIT loss and signature 5 mutations occur in all types of cancer; occur early in the neoplastic 
process and are age-associated (3-8, 11); loss of FHIT causes genome-wide DNA instability (1, 
2,11,12,13) and could, like loss/mutation of other caretaker genes, such as mismatch 
repair/BRCA1/2 genes, cause a specific mutational signature; the mutation profile of Fhit 
knockout mouse (ko) cells and tissues closely resembles mutational signature 5 (3, 5, 13) (see 
Fig 1B); the report of mutational consequences of smoking (14), comparing somatic mutations in 
smokers vs nonsmokers for smoking-associated cancers (Fig 1, for examples from ref 14); in Fig 
1B, signature 5 shows mutations across all 96 mutation subtypes, with more T>C and C>T 
mutations, similar to the signature of Fhit -/- kidney and other tissues, also shown in Fig 1B 
(5,14). Signature 5 mutations were found in all cancer types studied in ref 14, including cancers 
of nonsmokers. Striking findings in Fig 1 consistent with a role for FHIT/Fhit loss in production 
of signature 5 mutations were: these alterations occur early in the preneoplastic process and 
appear as clonal alterations in a tumor, just as alterations within the fragile FHIT locus are clonal 
in cancers and cancer cell lines (3, 11, 14-16).  
The discovery that Fhit loss is highly significantly associated with occurrence of mutational 
signature 5 in cancers suggested that loss of Fhit loss could be a marker for cancer development, 
as well as a target for prevention of cancer initiation (5). 
 
Fig 1. The mutational signatures in smoker’s vs nonsmokers. An abbreviated copy of the "smoking 
signatures" from ref 14, to emphasize features of this signature that suggested FHIT loss as cause of 
mutational signature 5: A, the mutation spectra in 25 randomly selected cancer genomes (individual bars 
from smokers or nonsmokers of a given cancer type).  Each bar is colored proportionately to the number of 
mutations/Mb of the specific mutational signatures found in the sample genome. Note signature 5 in kidney 
cancers; the FHIT gene was cloned due to a chromosome translocation within the gene in a hereditary kidney 
cancer family (16). B, patterns of mutational signatures 4 and 5 in tobacco smoker cancers as well as the 
mouse Fhit-/- signature in kidney tissue for comparison.  
 Loss of Fhit protein expression occurs due to replication stress at the FHIT locus, at very low 
levels in all individuals, likely in all normal tissues, and leads directly to genome-wide DNA 
instability in the Fhit-deficient cells, through reduced expression of the TK1 gene, needed for 
normal DNA replication, followed by accumulation of mutations in those cells (1,2). Subsequent 
mutation in genes which promote selective growth or survival in those Fhit-deficient cells, 
allows clonal expansion that can lead to precancerous lesions and cancers, particularly on 
exposure to DNA damaging agents. We can stop this genome instability and mutation 
accumulation in Fhit-deficient cells in tissue culture through supplementation with low dose 
thymidine in the culture medium (1, 2). We will determine if low dose thymidine 
supplementation can prevent genome instability in vivo, reduce mutation accumulation and 
prevent development of cancerous lesions in Fhit-deficient vs sufficient mice, without causing 
imbalance of cellular dNTP pools for DNA synthesis, a possible deleterious side-effect. 
Significant differences in cancer development in association with thymidine supplementation, 
will provide preclinical support for planning of prevention trials in humans at high-risk for 
cancer development, possibly including BRCA1 mutation carriers, Barrett’s esophagus patients 
at risk of progression to adenocarcinoma, or immunosuppressed transplant patients who may 
develop hundreds of precancerous skin or other lesions. 
Since 2013 when the first ‘mutational signatures’ report (3) appeared, analysis of >10,000 
sequenced cancers of 40 types has shown that the specific mutational signature 5, is clock-like 
(ie age associated), and occurs in all types of cancer (COSMIC website) (4). It has been reported 
that detection of this mutational signature in cancers is highly significantly associated with loss 
of expression of FHIT in these cancers (5). If it can be shown how to prevent Fhit-loss-induced 
genome instability, using mouse models carrying knocked-out Fhit or a conditionally expressed 
FhitTg in ko background, it will trail-blaze a prevention method that may be applicable to 
human preclinical trials, initially for high-risk cohorts and later possibly for other cancer types, 
since Fhit loss has been observed in every cancer type examined, and leaves its telltale footprint, 
‘mutational signature 5’.   
It is proposed that many of the ‘unavoidable’ mutations in cancer (9,10), such as the signature 5 
mutations associated with FHIT loss (5), are due to the genome-wide DNA instability introduced 
through alterations at the FHIT/FRA3B fragile locus. It is hypothesize that, since Fhit-loss 
associated genome-wide accumulation of mutations is a direct result of Fhit-loss-induced down-
modulation of Thymidine Kinase 1 (TK1) expression, needed for balanced intracellular 
thymidine pools for DNA synthesis, supplementation with low-dose thymidine could prevent 
development of genome instability and cancer development in mouse models exhibiting Fhit 
loss.  Thus, if FHIT gene/Fhit protein expression loss or subsequent genome-wide DNA 
instability could be prevented, many 'unavoidable' mutations and resulting precancers will be 
avoided. 
Aim: Pharmacologic/Nutritional strategy: Determine if thymidine supplementation 
suppresses Fhit loss-induced genome instability & tumor development in Fhit deficient 
mice. 
Methods:  
Protocol approved by the OSUMC IACUC. At the time of weaning (21 days of age), Aim 2 mice 
destined for the pharmacologic approach, are placed on standard diets with or without thymidine 
(1.8 g/kg thymidine, as described (31, 32), the dose used previously to evaluate the preventive 
effect of nucleoside–nucleotide supplementation on colonic mucosal damage in mice. Mice 
receiving the diet without thymidine are pair-fed to allow ingestion of the same amount as 
thymidine supplemented mice. Male and female mice 10 wks of age (20/genotype/procedure, 50% 
each gender); cohort sizes were determined by power analyses by Biostatistics co-I, Dr, Guy 
Brock, as described below. Smaller test cohorts of 8 mice per procedure with same timing and 
treatments, will be used for timed analysis of genome instability at 3- and 6-weeks post carcinogen 
(4 mice/cohort/procedure). The mice for tumor 
endpoint assessment (20 mice/treatment cohort) were 
sacrificed at 10 weeks post-carcinogen and the tissues 
were harvested for histological, IHC and other analyses 
as described previously (17, 28). Esophageal and 
forestomach epithelia are prepared for DNA isolation 
by using a blade to remove submucosal and muscularis 
layers (33) and epithelial DNA prepared for gel 
mobility comparisons. 
Tumorigenicity study. Mice of each genotype are 
produced in the in-house animal facility, treated with NMBA and analyzed as described previously 
(17). At autopsy, whole esophagi and forestomaches are removed and opened longitudinally for 
tumor count, inspection and fixation. The number of animals bearing tumors in the esophagus, 
forestomach, squamocolumnar junction with the glandular stomach are scored and differences in 
grossly observed lesion numbers are assessed using two-tailed Fisher's exact test. Tissues are fixed 
in buffered formalin and examined histologically after H&E staining for the presence and 
enumeration of hyperkeratosis, parakeratosis, dysplastic lesions, papillomas, adenomas, and 
carcinomas (as described in ref 17, 28, 33). 
RESULTS AND DISSUCSSION  
Upon dissection of the forestomaches, there was a visual difference between mice with the 
thymidine diets and the mice fed the normal diets treated with NMBA (Fig 3A). Both sets of mice 
Fig 2. Gross anatomy of murine forestomach 
after NMBA treatment. Typical aspects of 
NMBA-induced pathology in forestomachs of Fhit 
+/+ mouse (A), Fhit +/− mouse (B), Fhit −/− mouse 
(C), and Fhit −/− mouse (D) are shown. 
(Magnification: ×5) 
 
treated with NMBA showed thickening of the forestomaches but showed variability in number of 
tumors (Fig 3A). There was no difference in the types of tumors found between the two groups. It 
is suggested that a higher dose of thymidine may need to be administered in order to see statistical 
significance. Fig 3B showed a large subserosal lymph node aggregates present at the GE junction 
during histologic analysis. These seems to be larger and more present in FHIT +/- mice. Further 
studies must be done to show correlation.  
 
Fig 3: (A) Gross morphology photographs of forestomach of Fhit +/+ and NMBA treated Fhit +/- with and 
without thymidine diet. Some Fhit +/- animals NMBA treated with thymidine diet showed decreased tumor 
number and size. (B) Histologic analysis of mouse gastro-esophageal (GE) junction showed large subserosal 
lymph node aggregates present at the GE junction. 
CONCLUSION  
Higher dosage of Thymidine is needed to determine major difference between FHIT +/- and -/- 
mice in reducing NMBA-induced tumor growth. Some mice showed a reduction in tumor 
formation using a thymidine diet, however no major differences overall were shown. This 
suggests that the next step will be to increase the thymidine dose in order to see if thymidine can 
prevent genome instability. 
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